Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010;36:S21–9.

Article  CAS  PubMed  Google Scholar 

Hsu KH, Ho CC, Hsia TC, Tseng JS, Su KY, Wu MF, et al. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. PLoS ONE. 2015;10(3): e0120852.

Article  PubMed  PubMed Central  Google Scholar 

Chang GC, Yang TY, Chen KC, Hsu KH, Huang YH, Su KY, et al. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep. 2020;10(1):21063.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179–89.

Article  PubMed  Google Scholar 

Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer. 2023;4(3):330–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499–514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med. 2017;377(9):829–38.

Article  CAS  PubMed  Google Scholar 

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–39.

Article  CAS  PubMed  Google Scholar 

Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–29.

Article  CAS  PubMed  Google Scholar 

Gibson AJW, Box A, Dean ML, Elegbede AA, Hao D, Sangha R, et al. Retrospective real-world outcomes for patients with alk-rearranged lung cancer receiving ALK receptor tyrosine kinase inhibitors. JTO Clin Res Rep. 2021;2(4): 100157.

PubMed  PubMed Central  Google Scholar 

Lauppe R, Nilsson FOL, Fues Wahl H, Lilja M, Vikström A, S TA. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration—a Swedish nationwide retrospective study. Acta Oncol. 2022;61(11):1354–61.

Patel A, Batra U, Prasad KT, Dabkara D, Ghosh J, Sharma M, et al. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: a multicenter study from India. Curr Probl Cancer. 2020;44(3): 100571.

Article  PubMed  Google Scholar 

Tsimafeyeu I, Moiseenko F, Orlov S, Filippova E, Belonogov A, Nebesnykh A, et al. Overall survival of patients with ALK-positive metastatic non-small-cell lung cancer in the Russian federation: nationwide cohort study. J Glob Oncol. 2019;5:1–7.

PubMed  Google Scholar 

Condoluci A, Mazzara C, Zoccoli A, Pezzuto A, Tonini G. Impact of smoking on lung cancer treatment effectiveness: a review. Future Oncol. 2016;12(18):2149–61.

Article  CAS  PubMed  Google Scholar 

Zheng ZR, Ku HY, Chen KC, Chiang CJ, Wang CL, Chen CY, et al. Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma. Front Oncol. 2023;13:1063695.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–67.

Article  CAS  PubMed  Google Scholar 

Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.

Article  PubMed  Google Scholar 

Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–29.

Article  CAS  PubMed  Google Scholar 

Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017;8(58):98384–93.

Article  PubMed  PubMed Central  Google Scholar 

Tseng CH, Tsuang BJ, Chiang CJ, Ku KC, Tseng JS, Yang TY, et al. The relationship between air pollution and lung cancer in nonsmokers in Taiwan. J Thorac Oncol. 2019;14(5):784–92.

Article  CAS  PubMed  Google Scholar 

Chiang CJ, Wang YW, Lee WC. Taiwan’s nationwide cancer registry system of 40 years: past, present, and future. J Formos Med Assoc. 2019;118(5):856–8.

Article  PubMed  Google Scholar 

Chiang CJ, You SL, Chen CJ, Yang YW, Lo WC, Lai MS. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Jpn J Clin Oncol. 2015;45(3):291–6.

Article  PubMed  Google Scholar 

Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163–94.

Article  PubMed  Google Scholar 

Amin MB, Greene F, Edge SB, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

Google Scholar 

Edge SB, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging handbook. 7th ed. New York: Springer; 2009.

Google Scholar 

Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–64.

Article  CAS  PubMed  Google Scholar 

Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091–108.

Article  CAS  PubMed  Google Scholar 

Camidge DR. Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC. J Thorac Oncol. 2021;16(4):528–31.

Article  CAS  PubMed  Google Scholar 

Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol. 2018;36(22):2251–8.

Article  CAS  PubMed  Google Scholar 

Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol. 2019;14(4):691–700.

Article  CAS  PubMed  Google Scholar 

Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903–17.

Article  PubMed  PubMed Central